News

Healthcare providers have until September 23, 2013 to comply.

PACES trial will evaluate 2 drugs to prevent colon adenomas.

Employers bear a large number of costs.

Gifts to healthcare providers, including lunches, are now required to be tracked and reported.

The aim of these courses is to improve the care of patients aged 15-39.

More is now known about the types of HPV that increase risk.

Yes, it's been found there and on other surprising surfaces.

Standards established by an interprofessional workgroup.

Especially helpful for newly diagnosed patients.

OncLive is proud to announce that Emory University's Nell Hodgson Woodruff School of Nursing has joined its Strategic Alliance Partnership program.

New system hopes to improve toxicity grading accuracy.

Another year, another survivors' day.

New resource provides mechanism for viewing a hospital's billing track record.

Goal of proposed law is to improve patient care and reduce the nursing shortage.

A problem for many people undergoing cancer treatment.

Few baby boomers are facing the facts about aging.

USPSTF is inviting comments on screening by primary care professionals.

Melanoma is on the rise in children and teenagers.

The number of cancer survivors in the US continues to rise.

RNs with baccalaureate degrees provide the best post-surgical care.

A money-losing proposition for most practices.

Using different selection criteria for screening is superior to currently recommended criteria.

A consensus panel issues a set of discharge warning instructions regarding colorectal surgery.

The FDA has announced the approval of the first generic version of Doxil, which is expected to help alleviate a shortage of the drug that has continued since November 2011.

For the first time, Consumer Reports issues ratings of cancer screening tests.

An effective alternative to mastectomy for early stage disease regardless of age or hormone receptor status.

Screening rates are lower than desired, and disparities continue.

A pair of studies could change the way patients are evaluated for mutations of BRCA1 and BRCA2, two cancer susceptibility genes closely associated with breast and ovarian cancers, as well as other tumor types.

The FDA approved 11 new hematology-oncology drugs in 2012.

ASCO issues recommendations for improving cancer survivorship care.